Lentris 4mg

Lentris 4mg is a prescription medication used to treat certain types of cancer, including thyroid cancer, kidney cancer, and liver cancer. It is a kinase inhibitor that works by inhibiting the growth of cancer cells and reducing the production of new blood vessels that feed the tumor.

Composition:

• Lentris 4mg: Lenvatinib 4mg

Mechanism of Action:

Lenvatinib, the active ingredient in Lentris, is a tyrosine kinase inhibitor that works by:

1. Inhibiting the growth of cancer cells by blocking the action of specific enzymes that promote cell growth and division.
2. Reducing the production of new blood vessels that feed the tumor, which helps to reduce its growth and spread.
3. Inhibiting the activity of various signaling pathways that contribute to cancer cell growth and survival.

Indications:

Lentris is approved for the treatment of:

1. Advanced thyroid cancer (differentiated thyroid cancer) in patients who have not responded to other treatments.
2. Locally recurrent or metastatic renal cell carcinoma (RCC) in patients who have not responded to other treatments.
3. Hepatocellular carcinoma (HCC) in patients who have not responded to other treatments.

Dosage:

The recommended dosage of Lentris is:

• 4mg orally once daily, taken at the same time every day.
• The recommended duration of treatment is until disease progression or unacceptable toxicity.

Side Effects:

Common side effects of Lentris include:

1. Fatigue
2. Nausea
3. Vomiting
4. Diarrhea
5. Abdominal pain
6. Constipation
7. Increased risk of bleeding or bruising
8. Skin rash
9. Hair loss
10. Muscle pain

Recommendation:

Lentris is recommended for patients who have been diagnosed with thyroid cancer, kidney cancer, or liver cancer and have not responded to other treatments or have disease that has progressed after surgery and radiation therapy.

Important Note:

• Patients taking Lentris should be closely monitored for signs of bleeding or bruising due to the risk of thrombocytopenia.
• Patients taking Lentris should avoid taking medications that may increase the risk of bleeding or bruising.
• Pregnant or breastfeeding women should not use Lentris, as it may harm the fetus or infant.
• Regular follow-up appointments with your healthcare provider are necessary to monitor the effectiveness of Lentris and to detect any potential side effects or complications.

Special Precautions:

• Patients with a history of kidney disease should be closely monitored for signs of worsening kidney function while taking Lentris.
• Patients taking Lentris should avoid taking medications that may interact with it, such as anticoagulants or medications that can increase blood pressure.
• Patients with a history of heart disease or high blood pressure should be closely monitored while taking Lentris.

Contraindications:

• Patients with severe liver disease or severe kidney disease should not use Lentris.
• Patients who are allergic to lenvatinib or any other component of Lentris should not use it.
• Patients who are pregnant or breastfeeding should not use Lentris.